Ulcerative colitis: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• NLRP3 0
• NRF2 0
• STAT3 0
• JAK 2
• TNF 2
• IL-23 5
• TLR4 0
• MAPK 0
• PI3K 0
• PPAR 0
• AKT 0
• STING 0
• mTOR 0
• AMPK 0
• IL-6 0
• HIF-1 0
• TP53 0
• COX-2 0
• IL-17 0
• SIRT1 0
• CTNNB1 0
• GLP-1 0
• HMGB1 0
• HSP90 0
• IL-1 0
• CD40 0
• HDAC 1
• MMP-9 0
• GPX4 0
• JNK 0
• YAP 0
• EGFR 0
• CD19 3
• CTLA-4 0
• IL-4 0
• METTL3 0
• PARP 0
• VEGF 0
• BCMA 3
• ERK 0
• FOXP3 0
• MUC1 0
• PINK1 0
• ACE2 0
• G6PD 0
• IL-15 1
• KEAP1 0
• LRRK2 0
• MDM2 0
• PD-1 0
• PD-L1 0
• PKM2 0
• TIGIT 0
• BRD4 0
• CCR5 0
• CD30 0
• EZH2 0
• IL-13 0
• MYC 0
• PDE4 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Microbiota-Ulcerative Colitis INterface: Phage-bacteria-immune interactions at the mucosal level. (MUCIN)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €217,076· until Apr 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Characterising the molecular and cellular basis of enteric nervous system alterations in the inflamed gut (NeurogENSity)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €206,888· until Aug 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A Fibroblast-Targeting Advanced Lead Mitigating Inflammation and Fibrosis in IBD (FIBROLEAD)

  Inolysis Monoprosopi Idiotiki Kefalaiouchiki Etaireia· Melissia Athens, Greece· EU contribution €150,000· until Jan 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Unravelling neuroimmune crosstalk to find novel treatment targets for inflammatory bowel disease (UNTANGLED)

  Stichting Amsterdam Umc· Amsterdam, Netherlands· EU contribution €432,468· until Apr 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Interplay of epithelial mechanics and neutrophil activation as a pathomechanism in refractory IBD and colorectal cancer patients (INTERCONNECTIONS)

  Universitatsklinikum Erlangen· Erlangen, Germany· EU contribution €173,847· until Dec 2026

5 of 10 running projects, newest first. Listed amounts together: €19.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Study on Variation of Serum and Fecal Biomarkers After Treatment to Predict Mucosal Healing in Patients With Ulcerative Colitis

  NCT07653750· University Hospital, Clermont-Ferrand· Updated 17 Jun 2026

  “We were able to test our hypothesis using the current data”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 25
• Organoids 15
• Mendelian Randomization Analysis 48
• Gene Expression Profiling 76
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 5
• Proteomics 29
• Metabolomics 48
• Mass Spectrometry 5
• Flow Cytometry 8
• Immunohistochemistry 18
• Magnetic Resonance Imaging 10
• Machine Learning 43
• Deep Learning 11
• Cohort Studies 90
• Genome-Wide Association Study 56

• MUC5AC, CEACAM7, and DUOX2 Distinguish Colitis-associated Cancer from Sporadic Colorectal Cancer.

  Anticancer Res, Aug 2026

• Association between mucus phenotypes, histopathological features, and ultra-high magnification endoscopic findings in ulcerative colitis.

  Sci Rep, May 2026

• REG3A: A Potential Fecal Biomarker for Ulcerative Colitis.

  Mediators Inflamm, Jan 2026

• Targeting Molecular Dysregulation in Ulcerative Colitis: A Paired Cellular Perspective on CD4+, CD8+, and IL-6 Immunohistochemistry.

  Int J Mol Sci, Dec 2025

• The Colonic Vitamin D Receptor and Inflammatory Bowel Disease: No Correlation to Histologic or Endoscopic Inflammation.

  APMIS, Jan 2025

• Metformin-Inducible Small Heterodimer Partner Interacting Leucine Zipper Protein Ameliorates Intestinal Inflammation.

  Front Immunol, Jun 2021

• Serum vitamin D and colonic vitamin D receptor in inflammatory bowel disease.

  World J Gastroenterol, Apr 2016

• Medical ozone treatment ameliorates the acute distal colitis in rat.

  Acta Cir Bras, Apr 2016

• Human gastroenteropancreatic expression of melatonin and its receptors MT1 and MT2.

  PLoS One, Mar 2015

• Altered human gut dendritic cell properties in ulcerative colitis are reversed by Lactobacillus plantarum extracellular encrypted peptide STp.

  Mol Nutr Food Res, Dec 2013

See which targets of this disease your abstract mentions, and go to the people working on them.